ClinicalTrials.gg
RecruitingNCT07399327THALPOUpdated Jun 26, 2026

Biomarkers of Response to SEEG Thermocoagulation

An interventional study of Quality of life questionnaires (QOLIE, EFIQUACEE for children), psychiatric questionnaires (NDDIE, GAD-7, PCL-5) at Visit 1 (V1), V5, V6 and V7 and Resting state SEEG recording 30min before and 30 min after RFTC in Drug Resistant Epilepsy, sponsored by Assistance Publique Hopitaux De Marseille. Recruiting at 1 site in France. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-06-26.

Sponsored by Assistance Publique Hopitaux De Marseille · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
45
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 35 studies in Drug Resistant Epilepsy with a site in France — 16 open to participants now, 17 under way, 1 of them phase 3. Drug Resistant Epilepsy · France.

Planned enrollment
16th of 24
45 · median 82
Started
2026
with 4 others
No phase
12 of 35
8 open now
Primary completion
2029-01
later than 13 of 16 live
Registered
32nd of 35
by date
Lead sponsor
3 of 35
Assistance Publique Hopitaux De Marseille

Among the 35 studies in Drug Resistant Epilepsy with a site in France, this one is the 16th largest by planned enrollment of the 24 interventional ones that give a count, is one of 5 that started in 2026, is one of 12 with no phase, reaches primary completion later than 13 of the 16 other live ones, and was the 32nd registered.

Drug Resistant Epilepsy

258 studies on the registry are indexed under Drug Resistant Epilepsy; 109 are open to participants now.

Browse Drug Resistant Epilepsy studies →

Open to participants now

16 of the 35 studies in Drug Resistant Epilepsy with a site in France are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 68 Drug Resistant Epilepsy studies recruiting now, 27 (40%) set no upper age limit and 40 (59%) stop at 75 or younger; 27 take children under 18; 6 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Drug Resistant Epilepsy with a site in France, or all of them as a file.
02

Study summary

Drug-resistant focal epilepsy is a severe neurological disease that affects one-third of patients with epilepsy. Surgery is the only potentially curative treatment. Intracerebral exploration by stereo electroencephalography (SEEG) is an important step in the surgical pathway. It aims to establish the precise mapping of the epileptogenic network (EZN), including all the brain regions that generate seizures. At the end of SEEG, SEEG-guided radiofrequency thermocoagulation (SEEG RFTC) represents a therapeutic option that may be efficient as a palliative treatment in patients ineligible for resective surgery, or may lead, in some cases, to a definitive effect, avoiding open surgery. The safety and effectiveness of this approach have been established. However, the odds of remaining seizure-free after one year vary greatly between studies, ranging from 4% to 71%. This disparity in therapeutic responses could be linked to the absence of objective criteria for the selection of targets, but also to the existence of mechanisms of action outside of the direct lesional effect. A decrease in SEEG markers of epileptogenicity may predict thermocoagulation efficiency. However, no data are available regarding changes in alteration of the blood-brain barrier (BBB) connectivity, inflammation, or associated molecular changes and their relationship to prognosis.

This study aims to elucidate the mechanisms underlying the clinical effect of SEEG RFTC by studying the changes in electrophysiological (SEEG), structural (ultra-high field MRI), and biological (blood biomarkers of neuro-glio-vascular damage and inflammation, molecular adaptations) markers. They will be correlated with clinical outcome in a prospective cohort of patients with drug-resistant focal epilepsy. As advantages for clinical care, this study will allow selection of RFTC targets based on scientifically validated criteria, and elaboration of predictive scores for therapeutic response in each patient.

The primary objective is to study the predictive factors of response to SEEG RFTC, by correlating changes in BBB permeability with clinical response 3 months after RFTC, in a prospective cohort of patients with drug-resistant focal epilepsy.

03

Conditions studied

  • Drug Resistant Epilepsy

Keywords

  • RFTC
  • Drug resistant epilepsy
  • SEEG
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient, parents or legal representative who have given their written ,
  • Adult or pediatric patient ≥ 12 years old suffering from drug-resistant focal epilepsy,
  • Standardized pre-surgical assessment including medical history, scalp video-EEG and 3T MRI,
  • Patients in whom a SEEG exploration for pre-surgical evaluation has been indicated,
  • Patient able to understand, speak and write in French,
  • Patient able to follow study's procedure,
  • Patient beneficiary or affiliated to a health insurance plan.

Exclusion criteria

Exclusion Criteria:

  • Epilepsy surgery performed without the requirement of SEEG,
  • to 3T or 7T brain MRI (patient with a cardiac pacemaker, metallic foreign bodies, non-removable implanted electronic medical devices, claustrophobia, inability to remain in supine position, patient havingwith Vagus Nerve Stimulation (VNS) or Deep Brain Sstimulation (DBS), intrauterine devices or tattoos in the imaging area less than 6 weeks old at the time of the 3T/7T brain MRI),
  • Contraindication to gadolinium-based MRI contrast agent (history of allergic or anaphylactic reaction to gadolinium, to gadoteric acid, meglumine, or any drug containing gadolinium, severe renal failure (, GFR, below 30 ml/min/1.73 m2), patients on dialysis or with a history of kidney disease, such as renal transplantation, a single kidney, or renal ),
  • Person protected by articles L1121-5, L1121-6 and L1121-8 of the Public Health Code (pregnant or breastfeeding woman, deprived of liberty by judicial decision, situations of social fragility, adults unable or unable to express their consent),
  • Patient in exclusion period of another study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
45 participants (estimated)

Study arms

  • Experimental
    SEEG patients

    Other: Quality of life questionnaires (QOLIE, EFIQUACEE for children), psychiatric questionnaires (NDDIE, GAD-7, PCL-5) at Visit 1 (V1), V5, V6 and V7 · Other: Resting state SEEG recording 30min before and 30 min after RFTC · Other: Blood sample at Visit 1 (V1), V2, V4 and V5 · Other: SEEG electrodes tissue-traces sample at V3 (during SEEG electrodes ablation) · Other: Multiparametric 3T MRI with gadolinium at V1, V4 and V5 · Other: Multiparametric 7T MRI at V1 and V5

Interventions

  • OtherQuality of life questionnaires (QOLIE, EFIQUACEE for children), psychiatric questionnaires (NDDIE, GAD-7, PCL-5) at Visit 1 (V1), V5, V6 and V7

    This intervention consists in the completion of diverse questionnaires assessing the quality of life of the subject. These questionnaires include: * quality of life questionnaires: QOLIE or EFICACEE for children * psychiatric questionnaires NDDIE, GAD-7, PCL-5 These questionnaires will be performed during V1, V5, V6 and V7

  • OtherResting state SEEG recording 30min before and 30 min after RFTC

    During this intervention a resting state SEEG recording will be performed before and after RFTC. These recordings will last for 30 minutes each.

  • OtherBlood sample at Visit 1 (V1), V2, V4 and V5

    Blood samples will be collected at Visit 1 (V1), V2, V4 and V5. 2 tubes of 2 ml EDTA will be collected during these visits

  • OtherSEEG electrodes tissue-traces sample at V3 (during SEEG electrodes ablation)

    During this intervention, investigators will collect brain tissue samples on SEEG electrodes during their extraction.

  • OtherMultiparametric 3T MRI with gadolinium at V1, V4 and V5

    3T MRI with gadolinium injections will be performed at V1, V4 and V5.

  • OtherMultiparametric 7T MRI at V1 and V5

    Patients will undergo 7T MRI at V1 and V5

06

What researchers measure

Primary outcomes

  1. Relationship between changes in the MRI biomarker of BBB permeability (the transfer coefficient, Ki) and clinical response (responder vs non responder) at 3 months after RFTC

    Correlation between changes in the MRI biomarker of BBB permeability (the transfer coefficient, Ki), assessed using 3T MRI before SEEG and 3 months after RFTC and clinical response (responder, non-responder) at 3 months after RFTC.

    Time frame: From baseline before SEEG to 3 months after RFTC

Secondary outcomes

  1. Relationship between changes in MRI biomarkers of microstructural damage, large-scale 7T structural connectivity and functional connectivity response at 3 months after RFTC.

    Correlation between changes in MRI biomarkers of microstructural damage (7T T1 longitudinal relaxation time, T2\* effective transversal relaxation time, and tissue susceptibility), large-scale 7T structural connectivity (connectivity strengths assessed using DWI MRI) and functional connectivity (Pearson's correlation coefficient using BOLD resting state fMRI) assessed using 7T MRI before SEEG and 3 months after RFTC, and the clinical response (responder, non responder) at 3 months after RFTC.

    Time frame: From baseline before SEEG to 3 months after RFTC.

  2. Relationship between changes in MRI biomarkers of BBB permeability, microstructural damage, large-scale 7T structural connectivity and functional connectivity and clinical response at 6-12 months after RFTC.

    Correlation between changes in MRI biomarkers of BBB permeability (transfer coefficient, Ki), microstructural damage (7T T1 longitudinal relaxation time, T2\* effective transversal relaxation time, and tissue susceptibility), structural connectivity (connectivity strengths assessed using DWI MRI), functional connectivity (Pearson's correlation coefficient using BOLD resting state fMRI), assessed using 3T/7T MRI before SEEG and 3 months after RFTC, and the clinical response (responder vs. non responder; percentage change in seizure frequency) at 6 months and 12 months after RFTC

    Time frame: From baseline before SEEG to 6 months and 12 months after RFTC

  3. Relationship between changes in interictal SEEG-biomarkers (spikes- and HFO rates, power spectrum density (PSD), functional connectivity and clinical response at 3, 6 and 12 months after RFTC.

    Correlations between changes in interictal SEEG-biomarkers (spikes and HFO rates, power spectrum density (PSD), functional connectivity assessed by non-linear correlation coefficient h2) after RFTC versus before RFTC and clinical response (responder vs non responder; percentage change in seizure frequency versus baseline before SEEG) at 3, 6 and 12 months after RFTC.

    Time frame: From 30 minutes before to 30 minutes after RFTC for SEEG biomarkers; from baseline before SEEG to 3, 6 and 12 months after RFTC for clinical response.

  4. Relationship between changes in blood biomarkers within 72h and 3 months after RFTC and clinical response at 3, 6 and 12 months after RFTC.

    Correlation between changes in blood biomarkers (including GFAP, S100b, NFL, UHCL1) within 72 hours and 3 months after RFTC versus before SEEG and clinical response (responder vs non responder; percentage change in seizure frequency versus baseline before SEEG) at 3, 6 and 12 months after RFTC.

    Time frame: From baseline to 72 hours and 3 months after RFTC for blood biomarkers; from baseline to 3, 6 and 12 months after RFTC (radiofrequency thermocoagulation) for clinical response

  5. Changes in epileptogenicity markers within and outside the Epileptogenic Zone Network (EZN) 24 hours after RFTC

    Comparison of omic profiles, specifically ictal epileptogenicity markers EI (Epileptogenicity Index) cEI (connectivity Epileptogenicity Index) and PEI (Permutation Entropy Index) within and outside the Epileptogenic Zone Network (EZN) 24 hours after RFTC

    Time frame: Within 24 hours after RFTC (during SEEG electrode ablation)

  6. Changes from baseline in the quality of life questionnaire scores at 3-6-12 months after RFTC.

    Changes in QOLIE scale (Quality of Life in Epilepsy Inventory-Form 31, 0 to 100, 100 being the best outcome) for adults or EFIQUACCE (its equivalent for children) from baseline, which were assessed before SEEG and at 3, 6, and 12 months after RFTC.

    Time frame: From baseline before SEEG to 3 months, 6 months and 12 months after RFTC.

  7. To compare between groups the psychiatric impact (depression and anxiety)

    Changes between groups of psychiatric comorbidities, specifically depression: score of the NDDI-E (Neurological Disorders Depression Inventory for Epilepsy, 6 to 24, 24 meaning bad outcome), PCL-5 (Post-Traumatic Stress Disorder Checklist for DSM-5, 0 to 52, 52 being the worst outcome) and anxiety: Score of GAD-7 (Generalized Anxiety Disorder - 7, between 0 and 21, 21 meaning bad outcome)

    Time frame: From baseline before SEEG to 3 months, 6 months and 12 months after RFTC

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Jan 2029, 31 months after the start.

Of 90 non-industry interventional studies with no phase under Drug Resistant Epilepsy, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 21. This study's planned 31 months is close to that.

Counting every sponsor, half of 102 studies reached it within 34 months; a quarter within 21 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2026
First posted
Feb 10, 2026
StartActual
Jun 19, 2026
Primary completionEst.
Jan 31, 2029
CompletionEst.
Jun 30, 2029
Last update
Jun 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07399327
Collaborators
CRMBM-CEMEREM, UMR 5203, InsermU1191, IGF, Montpellier, Aix Marseille Université
Responsible party
Sponsor
First posted
Feb 10, 2026
Start date
Jun 19, 2026
Primary completion
Jan 31, 2029 (estimated)
Completion
Jun 30, 2029 (estimated)
Last update
Jun 26, 2026

Study contacts

Julia MAKHALOVA-SCHOLLY
Contact
Julia.SCHOLLY@ap-hm.fr
0491384990 ext. 33

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion